JAK inhibitors have been used to treat inflammatory conditions of some inborn errors of immunity: STAT3 and STAT1 gain-of-function mutations and type I interferonopathies, but there are as far as we know no reports of their use in CVID or GLILD. The gene discussed is STAT3; the disease is common variable immunodeficiency.